Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
暂无分享,去创建一个
[1] I. Ellis,et al. Radiotherapy and/or Tamoxifen after conserving surgery for breast cancers of excellent prognosis: BASO II trial , 2007 .
[2] J. Bryant,et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. , 2001, Journal of the National Cancer Institute.
[3] E. Rutgers,et al. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group. , 2007, European journal of cancer.
[4] R. Young,et al. Fox Chase Cancer Center , 2020, Definitions.
[5] R Peto,et al. Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care , 2011, British Journal of Cancer.
[6] W. Eiermann,et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] L. Ford,et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.
[8] C K Osborne,et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] C. Geyer,et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma , 2005, Cancer.
[10] M. Namer,et al. Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] D. Wickerham,et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Norman Wolmark,et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Timothy L Lash,et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Gelber,et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Prescott,et al. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. , 2001, Journal of the National Cancer Institute.
[16] H. Fukuda,et al. European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .
[17] H. Johansson,et al. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer , 2007, Acta oncologica.
[18] D. Tu,et al. A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12). , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] R. Gelber,et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] T. Delozier,et al. Adjuvant tamoxifen in postmenopausal breast cancer: Preliminary results of a randomized trial , 2005, Breast Cancer Research and Treatment.
[21] M. Schumacher,et al. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A M Thompson,et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer , 2008, British Journal of Cancer.
[23] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[24] P. Sismondi,et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] ADJUVANT TAMOXIFEN IN THE MANAGEMENT OF OPERABLE BREAST CANCER: THE SCOTTISH TRIAL Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh , 1987, The Lancet.
[26] D. Tormey,et al. The Eastern Cooperative Oncology Group , 1994 .
[27] S. Martino,et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Edith A Perez,et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] B Fisher,et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. , 1996, Journal of the National Cancer Institute.
[30] C. Osborne,et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J. Cuzick,et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.